

13 April 2026

## Completion of CannPal Asset Acquisition and Neuvis® Option

### Highlights:

- **Argent completes acquisition of CannPal animal epilepsy asset from AusCann Group Holdings Ltd**
- **Transaction includes option to acquire Neuvis® drug delivery platform**
- **CannPal provides Phase 3 veterinary epilepsy programme with near-term commercial potential**
- **Acquisition strengthens CannEpil® clinical, regulatory, and data positioning**

**Argent BioPharma Ltd (ASX: RGT) (Argent or the Company)** is pleased to confirm that, following shareholder approval at the recent General Meeting, it has completed the acquisition of AusCann Group Holdings Ltd's interest in CannPal Animal Therapeutics Pty Ltd (**CannPal**), together with an option to acquire the Neuvis® drug delivery platform.

### About CannPal

CannPal is a veterinary pharmaceutical development programme focused on the treatment of epilepsy in companion animals, with its lead asset targeting seizure management in dogs. The programme has progressed through advanced clinical development and is currently positioned at Phase 3, with a defined regulatory pathway and potential for near-term commercialisation.

The CannPal dataset, including clinical and safety data generated to date, provides a valuable translational foundation that supports Argent BioPharma's broader neurological strategy, particularly in relation to CannEpil® and seizure-related indications

### Strategic Value to Argent BioPharma

The acquisition represents a targeted expansion of the Company's neurological and epilepsy-focused portfolio.

Key strategic benefits include:

- Access to advanced-stage veterinary epilepsy programme with standalone commercial potential
- Integration of clinical and regulatory data supporting seizure management indications
- Strengthening of CannEpil®'s broader data package and positioning
- Optionality through Neuvis® drug delivery platform to enhance lifecycle management and formulation capabilities

### Neuvis® Option

As part of the transaction, Argent BioPharma has secured an option to acquire the Neuvis® drug delivery system, a proprietary oral delivery platform designed to enhance bioavailability and formulation performance.



Neuvis® has the potential to be applied across multiple assets within the Company's pipeline, supporting future product optimisation, lifecycle extension, and intellectual property consolidation.

### Strategic Significance

The completion of this acquisition marks a significant milestone in Argent BioPharma's development strategy, reinforcing its position as a neuro-immune focused biopharmaceutical company with both human and veterinary applications.

The addition of CannPal expands the Company's asset base with a late-stage programme capable of generating independent revenue, while also enhancing the scientific and regulatory framework underpinning CannEpi®.

This transaction further strengthens the Company's intellectual property position and aligns its portfolio with the requirements and scale expected of a U.S. national exchange listing.

### Argent BioPharma Managing Director and CEO, Roby Zomer, Commented:

*"The completion of the CannPal acquisition represents a strategically aligned step in strengthening Argent BioPharma's neurological portfolio. By adding a late-stage epilepsy programme with standalone commercial potential, while enhancing the data and positioning around CannEpi®, we are reinforcing both the depth and coherence of our asset base. The inclusion of the Neuvis® option further adds platform-level optionality as we continue to build a scalable and IP-driven pipeline aligned with our U.S. growth strategy."*

—Ends—

Authorised for release by the board of directors, for further information please contact:

#### Argent BioPharma

Roby Zomer  
CEO & Managing Director  
+61 8 6555 2950  
[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

#### Argent BioPharma


Rowan Harland  
Company Secretary  
+61 8 6555 2950  
[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

### About Argent BioPharma

**Argent BioPharma Ltd. (ASX: RGT)** is a revenue-generating, clinical-stage biopharmaceutical company focused on the development and commercialisation of nano-engineered therapeutics targeting neurological and immune-mediated disorders. Its lead assets, CannEpi® and CimetrA®, are being advanced for drug-resistant epilepsy and inflammatory conditions, respectively. The Company leverages proprietary nano-delivery technologies designed to optimise bioavailability and tissue penetration, including across the blood-brain barrier and pulmonary interfaces. With vertically integrated EU-GMP manufacturing, a unified Neuro-Immune Modulatory platform, and ongoing clinical development programs, Argent BioPharma is advancing a focused pipeline targeting central nervous system and systemic inflammatory conditions with significant unmet medical need

Follow us through our social media channels:

LinkedIn: Argent BioPharma  
Twitter: @ArgentBioPharma  
Facebook: Argent BioPharma



**Argent BioPharma Ltd**  
Suite 1, 295 Rokeby Road  
Subiaco, WA 6008, Australia

 +61 8 6555 2950

 [info@argentbiopharma.com](mailto:info@argentbiopharma.com)